Clinical Trial

A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated June 8, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open, multi-center clinical study designed to evaluate the safety, tolerability and efficacy of TQB3909 tablets in combination with azacitidine in subjects with myeloid malignancies.
Trial Details
NCT Number NCT07011186
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Myeloid Malignancy
Enrollment 138 participants
Start Date 2024-04-17
Primary Completion 2025-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-06-08